English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBafna pharmaceuticals

    Bafna Pharmaceuticals

    Jump to
    • Bafna Pharma Standalone March 2025 Net Sales at Rs 39.06 crore, down 5.65% Y-o-Y

      Bafna Pharma Standalone March 2025 Net Sales at Rs 39.06 crore, down 5.65% Y-o-Y

    • Bafna Pharma Standalone December 2024 Net Sales at Rs 33.19 crore, up 16.68% Y-o-Y

      Bafna Pharma Standalone December 2024 Net Sales at Rs 33.19 crore, up 16.68% Y-o-Y

    • Bafna Pharma Standalone September 2024 Net Sales at Rs 40.32 crore, down 0.87% Y-o-Y

      Bafna Pharma Standalone September 2024 Net Sales at Rs 40.32 crore, down 0.87% Y-o-Y

    • Bafna Pharma Standalone June 2024 Net Sales at Rs 33.29 crore, down 20.65% Y-o-Y

      Bafna Pharma Standalone June 2024 Net Sales at Rs 33.29 crore, down 20.65% Y-o-Y

    • Bafna Pharma Standalone March 2024 Net Sales at Rs 41.40 crore, down 2% Y-o-Y

      Bafna Pharma Standalone March 2024 Net Sales at Rs 41.40 crore, down 2% Y-o-Y

    • Bafna Pharma Standalone December 2023 Net Sales at Rs 28.44 crore, down 16.88% Y-o-Y

      Bafna Pharma Standalone December 2023 Net Sales at Rs 28.44 crore, down 16.88% Y-o-Y

    • Bafna Pharma Standalone September 2023 Net Sales at Rs 40.68 crore, up 85.23% Y-o-Y

      Bafna Pharma Standalone September 2023 Net Sales at Rs 40.68 crore, up 85.23% Y-o-Y

    • Bafna Pharma Standalone June 2023 Net Sales at Rs 41.95 crore, up 147.81% Y-o-Y

      Bafna Pharma Standalone June 2023 Net Sales at Rs 41.95 crore, up 147.81% Y-o-Y

    • Bafna Pharma Standalone March 2023 Net Sales at Rs 42.24 crore, up 181.96% Y-o-Y

      Bafna Pharma Standalone March 2023 Net Sales at Rs 42.24 crore, up 181.96% Y-o-Y

    • Bafna Pharma Standalone December 2022 Net Sales at Rs 34.22 crore, up 67.25% Y-o-Y

      Bafna Pharma Standalone December 2022 Net Sales at Rs 34.22 crore, up 67.25% Y-o-Y

    • Bafna Pharma Standalone June 2022 Net Sales at Rs 16.93 crore, down 20.38% Y-o-Y

      Bafna Pharma Standalone June 2022 Net Sales at Rs 16.93 crore, down 20.38% Y-o-Y

    • Bafna Pharma Standalone March 2022 Net Sales at Rs 14.98 crore, down 31.4% Y-o-Y

      Bafna Pharma Standalone March 2022 Net Sales at Rs 14.98 crore, down 31.4% Y-o-Y

    • Bafna Pharma Standalone December 2021 Net Sales at Rs 20.46 crore, up 17.08% Y-o-Y

      Bafna Pharma Standalone December 2021 Net Sales at Rs 20.46 crore, up 17.08% Y-o-Y

    • In talks with multinational pharma cos for acquisition of brands: Bafna Pharmaceuticals

      In talks with multinational pharma cos for acquisition of brands: Bafna Pharmaceuticals

      The company declared its financial results for the quarter ending September 30, 2021 with standalone net at Rs 2.37 crore as against Rs 47 lakh registered during same quarter of previous year.

    • Bafna Pharma Standalone June 2021 Net Sales at Rs 21.26 crore, up 27.28% Y-o-Y

      Bafna Pharma Standalone June 2021 Net Sales at Rs 21.26 crore, up 27.28% Y-o-Y

    • Bafna Pharma Standalone December 2020 Net Sales at Rs 17.48 crore, up 59.95% Y-o-Y

      Bafna Pharma Standalone December 2020 Net Sales at Rs 17.48 crore, up 59.95% Y-o-Y

    • Bafna Pharma Standalone March 2020 Net Sales at Rs 13.13 crore, up 38.32% Y-o-Y

      Bafna Pharma Standalone March 2020 Net Sales at Rs 13.13 crore, up 38.32% Y-o-Y

    • Bafna Pharma Standalone June 2019 Net Sales at Rs 6.85 crore, down 42.69% Y-o-Y

      Bafna Pharma Standalone June 2019 Net Sales at Rs 6.85 crore, down 42.69% Y-o-Y

    • Bafna Pharma Standalone December 2018 Net Sales at Rs 13.07 crore, up 20.37% Y-o-Y

      Bafna Pharma Standalone December 2018 Net Sales at Rs 13.07 crore, up 20.37% Y-o-Y

    • Stocks in news: Aurobindo, NALCO, Dabur, Manaksia, BEML, Sobha

      Stocks in news: Aurobindo, NALCO, Dabur, Manaksia, BEML, Sobha

      Tata Steel | ITC | Aurobindo Pharma | NALCO | Dabur | Burnpur Cement | Manaksia Industries | KEI Industries | Brigade Enterprises | S H Kelkar | VST Tillers | Granules | Sobha | BEML and Pokarna are stocks, which are in the news today.

    • Stocks in news: Tata Steel, BPCL, Bajaj Auto, Tata Elxsi

      Stocks in news: Tata Steel, BPCL, Bajaj Auto, Tata Elxsi

      VEDAVAAG Systems | Swaraj Automotives | Hisar Metal | Tata Steel | Steel Authority of India | HDFC Bank | Canara Bank | Dewan Housing Finance Corporation | Bharat Petroleum Corporation | Mahindra and Mahindra | Bajaj Auto | Fortis Healthcare | BGR Energy | MBL Infrastructures and Sun Pharmaceutical Industries are stocks, which are in news today.

    • Stocks in news: ITC, Maruti, Eicher, MOIL, Mukand, Hathway Cable

      Stocks in news: ITC, Maruti, Eicher, MOIL, Mukand, Hathway Cable

      ITC | Maruti Suzuki | Eicher Motors | Bombay Dyeing | HT Media | Muthoot Finance | Ujaas Energy | MOIL | Hathway Cable | Siemens | Navneet Education | Premier Explosives | Mukand | Bharti Infratel and Petronet LNG are stocks, which are in the news today.

    • Stocks in news: Torrent Power, GAIL, IOC, Eros, Aptech, Subros

      Stocks in news: Torrent Power, GAIL, IOC, Eros, Aptech, Subros

      Coal India | Torrent Power | GAIL | IOC | HPCL | BPCL | Eros International | Uttam Galva | Aptech | MRPL | Bafna Pharma | Indo Gulf Industries | K P Energy | NDTV | Ramco Systems | Subros and Tata Chemicals are stocks, which are in the news today.

    • Top buzzing midcap stocks to trade on June 10

      Top buzzing midcap stocks to trade on June 10

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have - Nestle India, Bharti Airtel, SPARC, Kaveri Seeds, Bafna, Amara Raja, Shree Renuka, Oberoi Realty, SPIC and Mangalore Chemicals.

    • Here are top 10 stocks to focus on March 17

      Here are top 10 stocks to focus on March 17

      Here are top 10 stocks to focus on March 17 - HCL Technologies, Jet Airways, Dr Reddys, Hindustan Unilever (HUL), HDFC Bank, Bank of Baroda, Amtek Auto, Indian Hotel, BHEL and Zee Media.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347